Author:
Guo Fang,Liu Zhaozhe,Liu Hongbo,Xie Xiaodong
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol, 2009, 39: 217–224.
2. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 2008, 111: 27–44.
3. Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol, 2008, 19: 1261–1265.
4. Alsner J, Yilmaz M, Guldberg P, et al. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res, 2000, 6: 3923–3931.
5. He Q, Wang J, Shao YG, et al. Clinical-pathological characteristics and survival of triple negative breast cancer. Natl Med J China (Chinese), 2009, 89: 243–247.